Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Newborn screening methods for cystic fibrosis.

Bridget Wilcken1, Veronica Wiley

  • 1New South Wales Newborn Screening Programme, The Children's Hospital at Westmead, Sydney, Australia. bridgetw@chw.edu.au

Paediatric Respiratory Reviews
|November 25, 2003
PubMed
Summary

Newborn screening for cystic fibrosis (CF) uses immunoreactive trypsinogen levels in blood spots. Combining this with DNA testing improves detection, though sweat tests and genetic counseling are crucial for diagnosis and carrier identification.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How feasible is nutrition intervention research in eating disorders? Lessons learnt from a pilot parallel randomised controlled trial of tyrosine supplementation in adolescents with anorexia nervosa.

Journal of eating disorders·2024
Same author

Genotyping in patients with congenital adrenal hyperplasia by sequencing of newborn bloodspot samples.

Journal of pediatric endocrinology & metabolism : JPEM·2023
Same author

Outcomes of lowered newborn screening thresholds for congenital hypothyroidism.

Journal of paediatrics and child health·2023
Same author

Expanding the Australian Newborn Blood Spot Screening Program using genomic sequencing: do we want it and are we ready?

European journal of human genetics : EJHG·2023
Same author

Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study.

The Lancet. Child & adolescent health·2023
Same author

Newborn Screening for the Diagnosis and Treatment of Duchenne Muscular Dystrophy.

Journal of neuromuscular diseases·2022

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Newborn screening for cystic fibrosis (CF) has utilized immunoreactive trypsinogen (IRT) measurements in dried blood spots for over two decades.
  • While IRT is a primary screening tool, initial results in the first week of life often lack discrimination, necessitating repeat testing.
  • Advances in genetic understanding, including the identification of the cystic fibrosis transmembrane conductance regulator (CFTR) gene and common mutations, have enabled integrated screening protocols.

Purpose of the Study:

  • To describe the evolution and current practices of newborn screening for cystic fibrosis.
  • To highlight the integration of biochemical and genetic testing for improved diagnostic accuracy.
  • To address the implications of carrier identification and the need for genetic counseling.

Related Experiment Videos

Main Methods:

  • Measurement of blood immunoreactive trypsinogen (IRT) from dried blood spots as the primary screening method.
  • Integration of DNA testing for cystic fibrosis transmembrane conductance regulator (CFTR) mutations using the same blood sample.
  • Development of population-specific protocols considering diverse genetic backgrounds.
  • Confirmation of diagnosis via sweat testing when indicated by genetic results.

Main Results:

  • Newborn screening for CF is increasingly adopted, leveraging IRT and CFTR gene analysis.
  • Integrated screening protocols demonstrate high specificity, with a typical false-negative rate around 5%.
  • DNA testing necessitates sweat test confirmation for single-mutation findings, leading to unavoidable carrier identification.

Conclusions:

  • Combined IRT and DNA testing offers an efficient newborn screening strategy for cystic fibrosis.
  • Population-specific protocols and sweat test confirmation are essential for accurate diagnosis.
  • Genetic counseling is vital for families of identified carriers to manage implications effectively.